Clinical and Translational Oncology

, Volume 19, Issue 9, pp 1161–1167 | Cite as

Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer

  • A. Zapatero
  • M. Roch
  • D. Büchser
  • P. Castro
  • L. Fernández-Banda
  • G. Pozo
  • O. Liñán
  • C. Martin de Vidales
  • A. Cruz-Conde
  • F. García-Vicente
Research Article



To evaluate the impact of intensity-modulated radiotherapy (IMRT) with intra-prostate fiducial markers image-guided radiotherapy (IGRT) on the incidence of late urinary toxicity compared to 3D conformal radiotherapy (3DCRT) for patients with prostate cancer (PC).

Methods and materials

We selected 733 consecutive patients with localized PC treated with dose-escalation radiotherapy between 2001 and 2014. Eligibility criteria were radiation dose >72.0 Gy, no pelvic RT and minimum follow-up 24 months. 438 patients were treated with 3DCRT and 295 with IMRT. Acute and late urinary complications were assessed using the EORTC/RTOG and CTCAEs v3.0 definition. The Cox regression model was used to compare grade ≥2 urinary toxicity between both techniques. The median follow-up was 75 months (range 24–204).


The median isocenter radiation dose was 78.7 Gy for 3DCRT and 80.7 Gy for IMRT/IGRT (p < 0.001). The 5-year incidence of late grade ≥2 urinary toxicity was 6.4% for IMRT and 10.8% for 3DCRT [hazard ratio (HR) 0.575, p = 0.056]. The corresponding 5-year estimates of late grade ≥2 hematuria were 2% for IMRT and 5.3% for 3DCRT (HR 0.296, p = 0.024). On multivariate analysis, the antecedent of prior transurethral resection of the prostate was also a strong predictor of a higher risk of urinary complications (HR 2.464, p = 0.002) and of hematuria (HR 5.196, p < 0.001).


Compared with 3DCRT, high-dose IMRT/IGRT is associated with a lower rate of late urinary complications in spite of higher radiation dose.


Prostate cancer IMRT 3DCRT Urinary toxicity Late toxicity Hematuria 


Author contributions

All the authors have contributed sufficiently to the scientific work and therefore share collective responsibility and accountability for the results. All the authors have read, approved and consented to submit the manuscript. The manuscript is not under consideration for publication elsewhere.

Compliance with ethical standards

Funding sources

This work has no specific funding.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

For this type of study formal consent is not required.


  1. 1.
    Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, Stürmer T, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307:1611–20.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Al-Mamgani A, Heemsbergen WD, Peeters ST, Lebesque JV. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. IntJ Radiat Oncol Biol Phys. 2009;73:685–91.CrossRefGoogle Scholar
  3. 3.
    Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Pei X, Carver B, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84:125–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Singh J, Greer PB, White MA, Parker J, Patterson J, Tang CI, et al. Treatment-related morbidity in prostate cancer: a comparison of 3-dimensional conformal radiation therapy with and without image guidance using implanted fiducial markers. Int J Radiat Oncol Biol Phys. 2013;85:1018–23.CrossRefPubMedGoogle Scholar
  5. 5.
    Fonteyne V, Ost P, Vanpachtenbeke F, Colman R, Sadeghi S, Villeirs G, et al. Rectal toxicity after intensity modulated radiotherapy for prostate cancer: which rectal dose volume constraints should we use? Radiother Oncol. 2014;113:398–403.CrossRefPubMedGoogle Scholar
  6. 6.
    Michalski JM, Yan Y, Watkins-Bruner D, Bosch W, Winter K, Galvin JM, et al. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the RTOG 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys. 2013;87:932–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Zapatero A, Valcarcel F, Calvo FA, Algás R, Béjar A, Maldonado J, et al. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol. 2005;23:6561–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Zapatero A, Guerrero A, Maldonado X, Álvarez A, González-San Segundo C, Cabeza Rodríguez MA, et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localized prostate cancer (DART 01/05 GICOR): a randomized, controlled, phase 3 trial. Lancet Oncol. 2015;16:320–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Zapatero A, García-Vicente F, Modolell I, Alcántara P, Floriano A, Cruz-Conde A, et al. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect. Int J Radiat Oncol Biol Phys. 2004;59:1343–51.CrossRefPubMedGoogle Scholar
  10. 10.
    Sevillano-Martínez D, García-Vicente F, Zapatero A, Ferrer-Gracia C, Gómez-Barrado A, Pérez-González L, et al. Study on the use of gold seeds in prostate cancer treatment verification. Rev Fis Med. 2008;93:105–12.Google Scholar
  11. 11.
    Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:1124–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Wortel RC, Incrocci L, Pos FJ, van der Heide UA, Lebesque JV, Aluwini S, et al. Late side effects after image guided intensity modulated radiation therapy compared to 3D-conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. Int J Radiat Oncol Biol Phys. 2016;95:680–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Landoni V, Fiorino C, Cozzarini C, Sanquineti G, Valdagni R, Rancati T. Predicting toxicity in radiotherapy for prostate cancer. Physic aMedica. 2016;32:521–32.CrossRefGoogle Scholar
  14. 14.
    Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Eble MJ. Low-grade toxicity after conformal radiation therapy for prostate cancer—impact of bladder volume. Int J Radiat Oncol Biol Phys. 2006;64:835–41.CrossRefPubMedGoogle Scholar
  15. 15.
    Ahmed AA, Egleston B, Alcantara P, Li L, Pollack A, Horwitz EM, et al. A novel method for predicting late genitourinary toxicity after prostate radiation therapy and the need for age-based risk-adapted dose constraints. Int J Radiat Oncol Biol Phys. 2013;86:709–15.CrossRefPubMedGoogle Scholar
  16. 16.
    Harsolia A, Vargas C, Yan D, Brabbins D, Lockman D, Liang J, et al. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose–volume analysis of a phase II dose-escalation study. Int J Radiat Oncol Biol Phys. 2007;69:1100–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Rosewall T, Catton C, Currie G, Bayley A, Chung P, Wheat J, et al. The relationship between external beam radiotherapy dose and chronic urinary dysfunction. A methodological critique. Radiother Oncol. 2010;97:40–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Ghadjar P, Zelefsky MJ, Spratt DE, Munckaf Rosenschöld P, Oh JH, Hunt M, et al. The impact of dose to the bladder trigone on long-term urinary function after high-dose intensity-modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2014;88:339–44.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Peeters STH, Heemsbergen WD, Van Putten WL, Slot A, Tabak H, Mens JW, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005;61:1019–34.CrossRefPubMedGoogle Scholar
  20. 20.
    Skala M, Rosewall T, Dawson L, Divanbeigi L, Lockwood G, Thomas C, et al. Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:690–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Garcia-Vicente F, Zapatero A, Martin de Vidales C, Rodríguez G, Leaman O, Cruz-Conde A, et al. Predictors for late urinary toxicity after high-dose radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013;87(Suppl 2):S365–6.CrossRefGoogle Scholar
  22. 22.
    Budaüs L, Bolla M, Bossi A, Cozzarini C, Crook J, Widmark A, et al. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol. 2012;61:112–27.CrossRefPubMedGoogle Scholar
  23. 23.
    Zapatero A, García-Vicente F, Sevillano D, Martín de Vidales C, Ferrer C, Torres JJ, et al. Is hormone therapy a protective factor for late hematuria after high-dose radiotherapy in prostate cancer? Urology. 2008;72:1130–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Sandhu AS, Zelefsky MJ, Lee HJ, Lombardi D, Fuks Z, Leibel SA. Long-term GU toxicity after 3-dimensional conformal radiotherapy for prostate cancer in patients with prior history of transurethral resection. Int J Radiat Oncol Biol Phys. 2000;48:643–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Kim S, Moore DF, Shih W, Lin Y, Li H, Shao YH, et al. Severe genitourinary toxicity following radiation therapy for prostate cancer. How long does it last? J Urol. 2013;189:116–21.CrossRefPubMedGoogle Scholar
  26. 26.
    De Langhe S, De Meerleer G, De Ruyck K, Ost P, Fonteyne V, De Neve W, et al. Integrated models for the prediction of late genitourinary complaints after high-dose intensity modulated radiotherapy for prostate cancer: making informed decisions. Radiother Oncol. 2014;112:95–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003;21:3972–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Jani AB, Gratzle J. Late radiotherapy toxicity after prostate cancer treatment: influence of hormonal therapy. Urology. 2005;66:566–70.CrossRefPubMedGoogle Scholar
  29. 29.
    Lawton C, Bae K, Pilepich M, Hanks G, Shipley W. Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. Int J Radiat Oncol Biol Phys. 2008;70:437–41.CrossRefPubMedGoogle Scholar
  30. 30.
    Zapatero A, Guerrero A, Maldonado X, Álvarez A, González-San Segundo C, Cabeza Rodríguez MA, et al. Late radiation and cardiovascular adverse effects following androgen deprivation and high-dose radiotherapy in prostate cancer: results from the DART 01/05 randomized phase III trial. Int J Radiat Oncol Biol Phys. 2016;96:341–8.CrossRefPubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2017

Authors and Affiliations

  • A. Zapatero
    • 1
  • M. Roch
    • 1
  • D. Büchser
    • 1
  • P. Castro
    • 1
  • L. Fernández-Banda
    • 1
  • G. Pozo
    • 1
  • O. Liñán
    • 1
  • C. Martin de Vidales
    • 1
  • A. Cruz-Conde
    • 1
  • F. García-Vicente
    • 1
  1. 1.Department of Radiation Oncology, Hospital Universitario de La PrincesaHealth Research Institute IIS-IPMadridSpain

Personalised recommendations